n">(Reuters) - Eli Lilly and Co said its experimental breast cancer drug failed to improve patients' survival without their cancer worsening in a late-stage trial, dashing investors' hopes on one of the company's most talked-about drugs.
Lilly shares fell 5 percent in premarket trade.
The company said it does not plan to submit an approval application for the drug, ramucirumab, for treating advanced breast cancer.
However, a separate trial, testing the drug as a treatment for advanced gastric cancer, met the main goal of improving patients' survival.
Ramucirumab - deemed as one of Lilly's most promising experimental treatments - was being tested in combination with chemotherapy drug docetaxel, and compared with a placebo and docetaxel as initial treatment in patients with advanced breast cancer.
Lilly said it is determining next steps for patients enrolled in the breast cancer trial conducted along with Translational Research in Oncology, an international cancer research group.
Ramucirumab is also being tested in late-stage trials for treating cancers of the colon, lung and liver.
Lilly shares fell 5 percent to $50.14 in trading before the bell. They closed at $52.61 on the New York Stock Exchange on Wednesday.
(Reporting by Esha Dey in Bangalore; Editing by Sriraj Kalluvila)
United States
Canada
Mexico
United Kingdom
Australia
Hong Kong
Taiwan Sign In / Create an Account My Account MyLists eGifts Trends Help Share: function fbs_click() {u='http://www.shop.com/Breast+Cancer+Awareness+Moonbabie+Pin+Barbara-20158766-p+.xhtml?credituser=C9165543USA';t=document.title;window.open('http://www.facebook.com/sharer.php?u='+encodeURIComponent(u)+'&t='+encodeURIComponent(t),'sharer','toolbar=0,status=0,width=626,height=436');return false;}Pin It $('.twitter.popup').click(function(event) { var width = 575, height = 400, left = ($(window).width() - width) / 2, top = ($(window).height() - height) / 2, url = this.href, opts = 'status=1' + ',width=' + width + ',height=' + height + ',top=' + top + ',left=' + left; window.open(url, 'twitter', opts); return false; });
SHIPFREE or $5 Flat Rate Terms & ConditionsSHIPFREE eligibility only applies to Market America products and brands. All non-eligible item will be charged normal shipping rates.To qualify, orders must be at least $99 or more in qualifying products excluding taxes or other fees. All orders under $99 of qualifying products are eligible for $5 flat rate shipping.Items that qualify for SHIPFREE or $5 flat rate shipping will have a tag indicating it's eligibilitySHIPFREE and $5 Flat Rate are only available for shipping to U.S. delivery addresses in the 50 U.S. States and the U.S. Territories of American Samoa, Guam, Puerto Rico and the U.S. Virgin Islands as well as the BahamasApplies to APO/FPO addresses when using a United States Zip Code onlyWeekend delivery is unavailableAll returned deliveries due to undeliverability or refusal will be charged a normal shipping and handling fee if reshipment is requested. This fee is $7.50 or 7.5% of item cost, whichever is greater.We reserve the right to change or discontinue SHIPFREE at any time.AmtracoAll DepartmentsSaleMarket AmericaTrend ShopStoresAutoBabyBeautyBooksBusinessCamerasClothesCollectiblesComputersCraftsElectronicsFood and DrinkGardenHealth & NutritionHome StoreJewelryMoviesMusicParty SuppliesPet SuppliesPostersShoesSoftwareSports and FitnessToolsToysTravelVideo Games
function fbs_click() {u='http://www.shop.com/20158766-p+260.xhtml?vid=228177&credituser=C9165543USA';t=document.title;window.open('http://www.facebook.com/sharer.php?u='+encodeURIComponent(u)+'&t='+encodeURIComponent(t),'sharer','toolbar=0,status=0,width=626,height=436');return false;}
$24.00Your price:$24.00$1.68
Sales tax Sales tax applied in this state (USA only)